The U.S. Consumer Product Safety Commission issued a bulletin today about the "danger of popular Peloton Tread+ exercise machine after multiple incidents of small children and a pet being injured beneath the machines. The Commission has found that the public health and safety requires this notice to warn the public quickly of the hazard." The warning comes less than a month after Peloton itself released news of a child's death by a Peloton Tread+. The agency is continuing to investigate all known incidents of injury or death related to the Peloton Tread+. To date, CPSC is aware of 39 incidents including one death. CPSC staff believes the Peloton Tread+ "poses serious risks to children for abrasions, fractures, and death." It added, "In light of multiple reports of children becoming entrapped, pinned, and pulled under the rear roller of the product, CPSC urges consumers with children at home to stop using the product immediately." Reference Link

In an interview on CNBC's Mad Money, Jagdeep Singh said QuantumScape has always been transparent about its data and about work that still needs to be done. "We're confident that the numbers we have are groundbreaking," he added. Singh noted that QuantumScape's core people have been with company for ten years and are not simply looking to make fast money. "They're a long-term committed team on a mission," he said. When asked about Scorpion Capital's allegations, he claimed that some of their points are "absurd."

In an interview on CNBC's Mad Money, Dan Preston said Metromile's customers save 47% on average relative to fixed rate insurance. He added that the company's word of mouth advertising is very strong as clients tend to share their positive experiences with many others. Metromile's customer retention rate is comparably better than most insurers, Preston noted.

In a regulatory filing, BlackRock senior managing director Mark Wiedman disclosed the sale of 1,725 common shares of the company on April 16 at a price of $812.5268 per share.

Citadel Advisors disclosed a 5.8% stake in AST SpaceMobile, which represents over 3.01M shares. The filing does not allow for activism.

Afya announced the acquisition of 100% of the total share capital of Cliquefarma, a healthtech company operating a free-to-use website that tracks prescription drugs, cosmetics and personal hygiene product prices in Brazil. Users of Cliquefarma can search for medications or healthcare products and compare prices from over 5,000 pharmacies in Brazil. The traffic generated is monetized through a cost-per-click model, where drugstores pay for each click on their ads. In 2020 Cliquefarma generated traffic of 20M visitors and R$43.2M in gross merchandise volume, the latter representing a 52.9% growth compared to 2019. The aggregate purchase price is R$19M of which 84.2% paid in cash and 15.8% is paid in Afya stocks as the date hereof. An earn-out of R$3M can be paid related to product development. This aggregate purchase price is equivalent to a 4.1x gross revenue multiple for 2021 expected gross revenue.

The United Steelworkers said that the union has proposed returning to negotiations in-person with ATI to resolve the outstanding issues that led about 1,300 workers at nine facilities to strike over unfair labor practices on March 30, 2021. USW International Vice President David McCall, who chairs the union's negotiations with ATI, said that he hopes the overwhelming solidarity shown by the USW membership gives management an opportunity to show workers respect they have earned. "Our progress has been hindered at every step by the company dragging its feet and violating labor law," McCall said. "Now is the time for ATI to commit to resolve the outstanding issues in good faith at the bargaining table."

The U.S. FDA revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment failure, the FDA has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. Therefore, the agency determined that the criteria for issuance of an authorization are no longer met and has revoked the EUA. Reference Link

In a regulatory filing, Kforce disclosed that its CEO David Dunkel sold 50K shares of common stock on April 14th in a total transaction size of $2.8M, reducing his stake by about 6%.

In a regulatory filing, Oak Street Health disclosed that its Chief Medical Officer Griffin Myers sold 109.4K shares of common stock on April 15th in a total transaction size of $6.28M, reducing his stake by about 2%.

In a regulatory filing, Carl Icahn disclosed a 13.35% stake in Tenneco, representing 10,946,841 shares. The move decreases Icahn's stake from 14.03%. The filing allows for activism.

In a regulatory filing, PPD disclosed that its CEO David Simmons sold 100K shares of common stock on April 14th in a total transaction size of $4.2M, reducing his stake by about 7%.